MedTrace Logo

A Research in Pharmacogenomics and Accurate Medication of Risperidone

NCT03302364 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2019-08-29

No results posted yet for this study

Summary

Risperidone is a selective monoamine receptor antagonist. It plays an antipsychotic effect by antagonizing 5-HT2 / D2 receptor. As a second-generation antipsychotic drug, risperidone is metabolized to 9-hydroxy Risperidone in the body very quickly. There are individual differences in the pharmacokinetics and pharmacodynamics of risperidone. For example, CYP2D6 genotype can greatly affect the metabolism of risperidone, and provide evidence for adjusting the type and dose of medication to treat Schizophrenia. In this study, we will verify the correlation between the polymorphisms of genes related with risperidone drug metabolites, drug transporters, drug targets and drug metabolism, pharmacodynamics, adverse reactions in Chinese population, providing basis for clinical rational use of risperidone.

Conditions

Interventions

DRUG

Risperidone

patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment

Sponsors & Collaborators

  • Cui Yimin

    lead OTHER

Principal Investigators

  • Yimin Cui, Ph.D & M.D · Peking University First Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-22
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03302364 on ClinicalTrials.gov